Positive Results Of Bharat Biotech COVID-19 Vaccine “COVAXIN” In US

Hyderabad: Positive results have been seen in two and three-phase clinical trials conducted in America on Bharat Biotech’s Covid-19 vaccine Covaxin”.

US-based Accugen Inc has announced that the goals set in these tests have been achieved. It is noteworthy that Augen Inc has signed an agreement with Bharat Biotech to launch the Covaxin vaccine in the US. Accugen Inc has applied to the US Food and Drug Administration (USFDA) for approval of the vaccine “Covaxin”. Clinical tests were conducted as part of this.

419 volunteers from the US participated in their tests. They were given two doses of “The Covaxin” vaccine at an interval of 28 days and the results were analyzed. As the vaccine exhibits high immunogenicity, the major antigens of the virus, S-protein, RBD, Accugen Inc claims that it works by targeting N-protein. Vaccines currently available in the US only target the S-protein antigen. Compared to other inactivated vaccines, the adjuvant TLR7/8 against the “Covaxin” vaccine demonstrated a Th1-biased immune response, resulting in long-lasting memory B and T-cell responses.

Dr. Shankar Musumuri, Chairman and CEO of, Accugen Inc said that Covaxin has achieved positive results in Phase-2/3 trials and has reached a key milestone in the fight against Covid.

He said no adverse results were seen in clinical tests. Dr. Eric Feagle Ding, Chief of the Covid Taskforce at the New England Complex Systems Institute, stated that with the increasing number of Covid-19 cases, it is becoming clear that different vaccines are needed to protect people from it. With the positive results obtained in clinical trials, it seems that Accugen Inc. will accelerate the efforts to make the “Covaxin” vaccine available in the US. (Maxim News)

---

Next Story :

Now you can get the latest stories from Indtoday on Telegram every day. Click the link to subscribe.  Click to follow Indtoday’s Facebook page and Twitter and Instagram. For all the latest Hyderabad News updates